Septerna (SEPN) Stock Price

Septerna Price

NYSE·CLOSED
36.00
​
Market closed

Revenue has compounded at 1,644.5% per year over the past 2 years to 45.95 M USD. Septerna's net margin stands at -106.4%, down from 2,768.2% several years earlier. Analysts set a median price target of 50.00 USD, implying 38.9% above the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.

Septerna stock price

Access this data via the Eulerpool API

Septerna business model & stock analysis

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. The company is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Frequently asked questions about Septerna

Analysts currently set an average price target of 52.00 USD for the Septerna stock (median: 50.00 USD), implying +44.4 % versus the latest price. The consensus is based on 16 analyst ratings.

16 analysts currently rate the Septerna stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Septerna to generate revenue of 96.04 M USD and earnings per share of -1.35 USD.

Converted at the current exchange rate, the Septerna share trades at 32.12 EUR (36.00 USD).

The expected revenue of Septerna is 96.04 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Septerna is -59.75 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Septerna is currently -26.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Septerna stock.

The price-to-sales ratio (P/S) of Septerna is currently 16.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Septerna stock.

The Eulerpool Quality Score for Septerna is 2/10.

The ISIN of Septerna is US81734D1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Septerna is SEPN. The ticker symbol is used to trade Septerna shares on the stock exchange.

Fair ValueTerminal
32.40 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
353,469.23 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website septerna.com
Currency
USD
Initial public offering
Oct 25, 2024
ISIN
US81734D1046
Cusip
81734D104
Market capitalization
1.59 B USDSmall Cap
52-Week Range
PEG
-1.33
P/E ratio
P/Ee 2026
-26.67
P/Ee 2027
-15.80
P/Ee 2028
-13.32
P/Ee 2029
-9.69
P/Ee 2030
-8.91
P/Se
16.59
EV/EBIT
—
P/B Ratio
4.17
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-12.80 %
Last updated Oct 9, 2026, 7:26 AM

Septerna Peer Group

All fundamentals and in-depth analysis of Septerna

Our stock analysis for Septerna stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Septerna. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.